Baxter International
About: Baxter International Inc offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Employees: 38,000
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
3.55% more ownership
Funds ownership: 90.85% [Q3] → 94.4% (+3.55%) [Q4]
9% less funds holding
Funds holding: 879 [Q3] → 802 (-77) [Q4]
15% less call options, than puts
Call options by funds: $91.6M | Put options by funds: $108M
20% less capital invested
Capital invested by funds: $17.6B [Q3] → $14.1B (-$3.5B) [Q4]
25% less funds holding in top 10
Funds holding in top 10: 8 [Q3] → 6 (-2) [Q4]
26% less repeat investments, than reductions
Existing positions increased: 244 | Existing positions reduced: 328
34% less first-time investments, than exits
New positions opened: 110 | Existing positions closed: 167
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$36
26%
upside
Avg. target
$40
39%
upside
High target
$42
47%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
Barclays Matt Miksic 44% 1-year accuracy 18 / 41 met price target | 44%upside $41 | Overweight Maintained | 10 Mar 2025 |
Goldman Sachs David Roman 25% 1-year accuracy 5 / 20 met price target | 47%upside $42 | Buy Reinstated | 26 Feb 2025 |
JP Morgan Robbie Marcus 30% 1-year accuracy 6 / 20 met price target | 26%upside $36 | Neutral Maintained | 21 Feb 2025 |
Financial journalist opinion
Based on 4 articles about BAX published over the past 30 days
Positive
CNBC Television
4 days ago
Goldman's John Marshall provides stock opportunities ahead of earning season
John Marshall, Goldman Sachs head of derivatives research, joins 'Money Movers' to discuss the current market environment, individual companies Goldman looked at, and much more.
Neutral
Business Wire
1 week ago
Baxter Launches New Room Temperature Hemopatch Sealing Hemostat for Rapid and Convenient Application During Surgery
VIENNA--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today announced the introduction of Hemopatch Sealing Hemostat with room temperature storage at a symposium in Austria. The evolution of the product optimizes accessibility in the operating room, delivering an immediate solution for surgeons to control bleeding or prevent leakage. The product is now available to order throughout Europe. “For over a decade, Hemopatch Sealing Hemostat.
Neutral
Business Wire
1 week ago
Baxter Launches New Room Temperature Hemopatch Sealing Hemostat for Rapid and Convenient Application During Surgery
VIENNA--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today announced the introduction of Hemopatch Sealing Hemostat with room temperature storage at a symposium in Austria. The evolution of the product optimizes accessibility in the operating room, delivering an immediate solution for surgeons to control bleeding or prevent leakage. The product is now available to order throughout Europe. “For over a decade, Hemopatch Sealing Hemostat.
Neutral
Business Wire
3 weeks ago
Baxter to Host Annual Meeting of Stockholders in Virtual Format
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2025 Annual Meeting) in a virtual format on Tuesday, May 6, 2025 at 9 a.m., Central Time, as disclosed in Baxter's proxy statement for the 2025 Annual Meeting. Online access to the 2025 Annual Meeting will begin at 8:45 a.m., Central Time. Stockholders will not be able to attend the 2025 Annual Meeting in person. The virtual format provides a safe, c.
Positive
Market Watch
1 month ago
Stocks beating the stock market's recent Trump slump have this in common
This year's top performer among the S&P 500 has been CVS Health's stock, which had a bad 2024 and is cheap by a key valuation measure.
Positive
Zacks Investment Research
1 month ago
Baxter Stock Likely to Gain Following the Introduction of Voalte Linq
At the 2025 HIMSS Global Healthcare Conference, BAX unveils its Voalte Linq device, powered by Scotty assistant, a voice-activated technology.
Neutral
Business Wire
1 month ago
Baxter Unveils Voalte Linq Device Powered by Scotty Assistant at HIMSS25 to Advance Voice-Activated Technology in Hospital Settings
LAS VEGAS--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today unveiled Voalte Linq device powered by Scotty assistant, the company's first voice-activated technology, at the 2025 HIMSS Global Healthcare Conference. Voalte Linq, a lightweight, wearable badge, is powered by Scotty assistant, a voice-activated technology, to better enable efficient, streamlined communication between care teams, with the goal of freeing up more of their time and energy to focus on.
Neutral
GlobeNewsWire
1 month ago
Medical Penlight Market Report 2025-2030, with BV Medical, Aspen Surgical Products, Baxter, Streamlight, GF Health Products, Rudolf Riester, American Diagnostic, HONSUN, Prestige Medical & more
Dublin, March 03, 2025 (GLOBE NEWSWIRE) -- The "Medical Penlight Market Size, Share & Trends Analysis Report By Type (Consumables, Equipment), By Light Output (Oncology, Cardiovascular Diseases), By Usability (Disposable, Reusable), By End-use, By Region, And Segment Forecasts, 2025 - 2030" report has been added to ResearchAndMarkets.com's offering. The global medical penlight market size was estimated at USD 279.7 million in 2024 and is projected to grow at a CAGR of 6.6% from 2024 to 2030. The market is driven significantly by the product's utility in diagnosing and assessing eye and ear conditions. According to a WHO report from August 2023, approximately 2.2 billion individuals experience distance vision impairment. Out of this group, vision impairment in at least 1 billion cases could have been prevented or remains untreated. Refractive errors and cataracts are identified as the primary causes of vision impairment and blindness worldwide. Medical professionals rely on penlights for their compact size, ease of use, and focused illumination, which are crucial in conducting detailed examinations of these sensitive areas. In ophthalmology, penlights are indispensable tools for examining the pupils, assessing pupil reactions to light, and detecting abnormalities such as irregularities in pupil size or shape, which can indicate neurological or ocular health issues. They are also crucial in assessing eye movements and conducting basic visual acuity tests, aiding in the diagnosis of conditions such as strabismus or nystagmus. The increasing prevalence of eye and ear disorders, coupled with advancements in penlight technology, is driving market growth. Manufacturers are innovating with features such as LED illumination for brighter and more efficient light output, ergonomic designs for comfortable handling during prolonged use, and enhanced durability for reliability in clinical environments. These advancements not only improve diagnostic accuracy but also streamline workflow efficiency in healthcare settings. In addition, otolaryngology (ENT), medical penlights are used for examining the ear canal, tympanic membrane, and assessing hearing conditions. They help ENT specialists to visualize abnormalities, foreign objects, and signs of infection or inflammation within the ear. Worldwide, the incidence of ENT conditions such as laryngitis, tonsillitis, sinusitis, and hearing loss is increasing. According to the World Health Organization (WHO), over 10% of the global population currently experiences varying degrees of hearing loss, a figure projected to approach nearly 2 billion by 2050. Penlights equipped with otoscopic attachments further enhance their utility by enabling magnified views and facilitating detailed inspections of the ear's internal structures. This capability is crucial for diagnosing conditions such as otitis media, ear wax buildup, and tympanic membrane perforations. Furthermore, the emphasis on preventive healthcare and early diagnosis is further boosting the demand in the medical penlights market. Routine screenings and examinations using penlights help in identifying eye and ear conditions at their early stages, enabling timely interventions and improving patient outcomes. As healthcare facilities continue to prioritize patient care and diagnostic accuracy, the role of medical penlights in supporting comprehensive eye and ear health assessments is expected to expand, driving continued market growth in the coming years. Global Medical Penlight Market Report Segmentation This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For the purpose of this study, the analyst has segmented the medical penlights market report on the basis of type, light output, usability, end use and region.
Neutral
Business Wire
1 month ago
Baxter to Present at Barclays 27th Annual Global Healthcare Conference
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025. Joel Grade, Baxter's chief financial officer, is scheduled to present at 1:00 p.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Monday, September 8, 2025. About Baxter Every day, millions of patients, caregivers and.
Neutral
Zacks Investment Research
1 month ago
BAX Stock Surges Following Q4 Earnings & Sales Beat, Margins Decline
Baxter reports better-than-expected fourth-quarter results. However, the company's gross and operating margins contract.
Charts implemented using Lightweight Charts™